Clinical Trial Update: Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

View source ↗

Summary

A clinical trial update comparing an E. coli–expressed HPV nonavalent vaccine to Gardasil 9, reporting plateau antibody levels in young women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Condylomata Acuminata

Drugs mentioned

• Gardasil 9 (Human papillomavirus vaccine, 9-valent)
• HPV recombinant nonavalent vaccine (E. coli)

Snippet

Sponsor: Xiamen University | Conditions: Cervical Cancer, Condylomata Acuminata | Status: ACTIVE_NOT_RECRUITING